Satisfying needs for
niche Specialty Care products
00 / pharma& news
We are proud to announce that we recently signed an agreement
with F. Hoffmann-La Roche Ltd to acquire the worldwide rights of
Pegasys (Peginterferon alpha 2a) excl. China and Japan,
securing long-term access and supply for patients benefiting
from this well established therapy option.
For any inquiries please contact us at
01 / pharma& is
pharma& is a privately owned company, aiming at satisfying needs for niche, original, Specialty Care products.
Our commitment to patient access for well-established original Specialty Care medicines and our worldwide presence of own subsidiaries, affiliated companies and partnerships, secure sustainable product availibilty in markets around the world.
02 / pharma& story
After having acquired multiple products in various therapeutic areas and having established a profound base to secure patient access and to supply products across the entire European Landscape we have expanded our footprint to serve patients around the world.
We are proud of our “every patient counts” commitment and our strong partnership network.
03 / pharma& team
All of us have been trained over decades in Top Tier Global Pharmaceutical Companies, coming together as a team, committed and enjoying to grow together.
Supported by our trusted network of highly qualified service providers and experts, we want to shape our future and to leave footprints for the benefits of our patients, their caregivers and our stakeholders.
04 / pharma& founders
06 / pharma& pharmacovigilance contact
Bei Nebenwirkungen wenden Sie sich bitte an
oder schreiben Sie ein Email an firstname.lastname@example.org.
Zusätzlich können Sie auch direkt über die Homepage des Bundesamtes für Sicherheit im Gesundheitswesen (http://www.basg.gv.at) Nebenwirkungsfälle melden.
In case of adverse events, please contact
or send an Email to email@example.com.
Additionally, you can also report adverse events via your local health authorities.